# Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Study · id `cardio:ct-nct02545842` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02545842](<https://clinicaltrials.gov/study/NCT02545842>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02545842

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 947 participants.

## Technical summary

Registry record NCT02545842. Randomized; no masking; primary purpose treatment. Start 2015-09-07 (registry gives no type); primary completion 2018-04-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 947 participants (enrolled count; ClinicalTrials.gov record NCT02545842, source copy `cardio:ctgov-nct02545842-2022-04-25`, retrieved 2026-10-26)
- Start date: 2015-09-07 (registry gives no type) (ClinicalTrials.gov record NCT02545842, source copy `cardio:ctgov-nct02545842-2022-04-25`, retrieved 2026-10-26)
- Primary completion: 2018-04-20 (actual) (ClinicalTrials.gov record NCT02545842, source copy `cardio:ctgov-nct02545842-2022-04-25`, retrieved 2026-10-26)
- Completion: 2018-04-20 (actual) (ClinicalTrials.gov record NCT02545842, source copy `cardio:ctgov-nct02545842-2022-04-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02545842, source copy `cardio:ctgov-nct02545842-2022-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02545842-2022-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): INSULIN GLARGINE
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis (`cardio:pubmed-32671687`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III) (`cardio:pubmed-34757600`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study (`cardio:pubmed-35430674`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b8f344130df30acadc14fc2402fd88700093826d7a7697f46a6b0a40c83836f3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
